Skip to main content

NovalGen announces compelling data from the Phase 1/2 Study of NVG-111

A major breakthrough for NovalGen, announcing first clinical data from the ongoing Phase 1/2 study of NVG-111 in patients with Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.

 

London, United Kingdom, May 26, 2022 – NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, announces first clinical data from the ongoing Phase 1/2 study of NVG-111, a novel ROR1 targeting bispecific antibody T cell engager, in patients with relapsed and refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting McCormick Place, Chicago, IL, June 3 to 7, 2022. The Company will also be presenting additional clinical data at the conference.

Read the full story from NovalGen here.

 
NovalGen Logo